Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2024 | The potential role of NK cells in advanced breast cancer treatment

Margaret Gatti-Mays • 12 Dec 2024
SABCS 2024
Breast Cancer

Margaret Gatti-Mays, MD MPH, Ohio State University, Columbus, OH, hopes that universal donor natural killer (NK) cells can be used to enhance chemotherapy and immunotherapy in advanced breast cancer treatment by overcoming treatment resistance by tackling TGFβ and lead to improved clinical and patient outcomes in the future. This interview took place at 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Margaret Gatti-Mays

Strategies to overcome barriers in cancer vaccine efficacy
1:32
Strategies to overcome barriers in cancer vaccine efficacy
Margaret Gatti-Mays • 1 Jun 2025
Phase I trial of a therapeutic vaccine with checkpoint inhibitors for FLC
1:28
Phase I trial of a therapeutic vaccine with checkpoint inhibitors for FLC
Margaret Gatti-Mays • 1 Jun 2025
SYNC-T therapy: in situ personalized cancer vaccination with intratumoral immunotherapy in mCRPC
2:04
SYNC-T therapy: in situ personalized cancer vaccination with intratumoral immunotherapy in mCRPC
Margaret Gatti-Mays • 1 Jun 2025
Phase I study of B440, a WT1 cancer vaccine, in patients with metastatic urothelial cancer
1:40
Phase I study of B440, a WT1 cancer vaccine, in patients with metastatic urothelial cancer
Margaret Gatti-Mays • 1 Jun 2025

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
The content of VJOncology is intended for healthcare professionals